Research programme: peroxisome proliferator-activated receptor gamma agonist - OmerosAlternative Names: PPAR-gamma agonist
Latest Information Update: 04 May 2012
At a glance
- Originator Omeros Corporation
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Drug abuse
Most Recent Events
- 04 May 2012 Preclinical development is ongoing in USA
- 14 Aug 2009 Preclinical trials in Drug abuse in USA (unspecified route)